Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine

Abstract

Antiplatelet treatment for patients undergoing percutaneous coronary interventions is a rapidly changing area. Thienopyridines derivatives (ticlopidine and clopidogrel) have shown to decrease major cardiovascular events. Ticlopidine can cause rare but serious side effects, especially during the first 3 months of treatment. Clopidogrel appears to be a safer alternative to ticlopidine. However, resistance to clopidogrel therapy may increases the risk of recurrent cardiovascular events. Whether increased doses of clopidogrel might overcome this resistance in nonresponsive patients warrants further investigation. © 2005 Elsevier Ireland Ltd. All rights reserved.